Education
About Us
Working with TipRanks
Follow Us
Santen Pharmaceutical Co Ltd (SNPHY)
OTHER OTC:SNPHY
SNPHY Stock Chart & Stats
$11.00
-$0.45(-4.61%)
At close: 4:00 PM EST
$11.00
-$0.45(-4.61%)
Day’s Range― - ―
52-Week Range$9.15 - $11.85
Previous CloseN/A
Volume180.00
Average Volume (3M)1.01K
Market Cap
$3.52B
Enterprise Value$527.72B
Total Cash (Recent Filing)$61.59B
Total Debt (Recent Filing)$36.17B
Price to Earnings (P/E)18.3
Beta0.04
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.02%
Share Statistics
EPS (TTM)0.16
Shares Outstanding322,273,960
10 Day Avg. Volume2,904
30 Day Avg. Volume1,010
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.73
Price to Sales (P/S)1.65
P/FCF Ratio9.12
Enterprise Value/Market Cap149.98
Enterprise Value/Revenue1.82
Enterprise Value/Gross Profit3.28
Enterprise Value/Ebitda8.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetSanten’s low debt-to-equity (~0.13) and sizable equity base provide enduring financial flexibility. This conservative financing lowers refinancing risk, supports continued R&D and manufacturing investment, and creates capacity to absorb shocks or pursue strategic deals without levering up.
Sustained ProfitabilityHealthy gross and operating margins and a return to positive net margins indicate durable underlying profitability. Recovery from the 2023 loss to consistent TTM profits suggests effective cost control and pricing in core ophthalmology franchises, supporting long-term cash generation and reinvestment capacity.
Strong Cash GenerationRobust absolute operating and free cash flows with FCF covering most net income underpin the company’s ability to self-fund operations, R&D and capital spending. Positive cash generation reduces reliance on external financing and supports sustainable investment or shareholder returns over time.
Bears Say
Sharp Revenue DeclineA ~-74% TTM revenue contraction is a material structural headwind: it erodes market share, limits scale benefits, and undermines the sustainability of margins and R&D funding. Restoring top-line growth is essential for long-term earnings durability and competitive positioning.
Weakened Cash ConversionDeclining cash conversion and sharply negative free cash flow growth signal weakening operational cash momentum. Even with positive FCF in absolute terms, lower conversion reduces internal funding available for pipelines and capex, increasing exposure if revenue weakness persists.
Balance Sheet ContractionA downward trend in total assets and equity suggests balance-sheet contraction that can limit strategic flexibility. Shrinking asset and equity bases reduce the company’s cushion against shocks, may constrain scale economies, and could signal structural challenges to long-term growth.
Santen Pharmaceutical Co News
SNPHY FAQ
What was Santen Pharmaceutical Co Ltd’s price range in the past 12 months?
Santen Pharmaceutical Co Ltd lowest stock price was $9.15 and its highest was $11.85 in the past 12 months.
What is Santen Pharmaceutical Co Ltd’s market cap?
Santen Pharmaceutical Co Ltd’s market cap is $3.52B.
When is Santen Pharmaceutical Co Ltd’s upcoming earnings report date?
Santen Pharmaceutical Co Ltd’s upcoming earnings report date is May 12, 2026 which is in 70 days.
How were Santen Pharmaceutical Co Ltd’s earnings last quarter?
Santen Pharmaceutical Co Ltd released its earnings results on Feb 05, 2026. The company reported $0.158 earnings per share for the quarter, beating the consensus estimate of N/A by $0.158.
Is Santen Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Santen Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Santen Pharmaceutical Co Ltd pay dividends?
Santen Pharmaceutical Co Ltd pays a Semiannually dividend of $0.128 which represents an annual dividend yield of 2.02%. See more information on Santen Pharmaceutical Co Ltd dividends here
What is Santen Pharmaceutical Co Ltd’s EPS estimate?
Santen Pharmaceutical Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Santen Pharmaceutical Co Ltd have?
Santen Pharmaceutical Co Ltd has 322,273,960 shares outstanding.
What happened to Santen Pharmaceutical Co Ltd’s price movement after its last earnings report?
Santen Pharmaceutical Co Ltd reported an EPS of $0.158 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.775%.
Which hedge fund is a major shareholder of Santen Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in SNPHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Santen Pharmaceutical Co Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.01%
12-Months-Change
Fundamentals
Return on Equity
10.89%
Trailing 12-Months
Asset Growth
4.69%
Trailing 12-Months
Company Description
Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Technical Analysis
Ownership Overview
―
Insiders
0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---